Coy D. Heldermon

1.3k total citations
58 papers, 889 citations indexed

About

Coy D. Heldermon is a scholar working on Molecular Biology, Oncology and Physiology. According to data from OpenAlex, Coy D. Heldermon has authored 58 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 14 papers in Oncology and 12 papers in Physiology. Recurrent topics in Coy D. Heldermon's work include Lysosomal Storage Disorders Research (9 papers), Virus-based gene therapy research (6 papers) and RNA Interference and Gene Delivery (4 papers). Coy D. Heldermon is often cited by papers focused on Lysosomal Storage Disorders Research (9 papers), Virus-based gene therapy research (6 papers) and RNA Interference and Gene Delivery (4 papers). Coy D. Heldermon collaborates with scholars based in United States, Taiwan and Japan. Coy D. Heldermon's co-authors include Paul H. Weigel, Paul L. DeAngelis, Mark S. Sands, Valarie L. Tlapak‐Simmons, Carole Vogler, Lingbao Ai, Erik D. Herzog, Bruce A. Baggenstoss, Kevin D. Brown and Kevin K. Ohlemiller and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Coy D. Heldermon

53 papers receiving 878 citations

Peers

Countries citing papers authored by Coy D. Heldermon

Since Specialization

Citations

This map shows the geographic impact of Coy D. Heldermon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Coy D. Heldermon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Coy D. Heldermon more than expected).

Fields of papers citing papers by Coy D. Heldermon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Coy D. Heldermon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Coy D. Heldermon. The network helps show where Coy D. Heldermon may publish in the future.

Co-authorship network of co-authors of Coy D. Heldermon

This figure shows the co-authorship network connecting the top 25 collaborators of Coy D. Heldermon. A scholar is included among the top collaborators of Coy D. Heldermon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Coy D. Heldermon. Coy D. Heldermon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A High-Sensitivity, Bluetooth-Enabled PCB Biosensor for HER2 and CA15-3 Protein Detection in Saliva: A Rapid, Non-Invasive Approach to Breast Cancer Screening 2025 ·Biosensors ·(unknown), Chao-Ching Chiang, F. Ren, (unknown), (unknown), Catherine Chiu, Yu‐Te Liao, Dan Neal, Coy D. Heldermon, Mateus Garcia Rocha, Josephine F. Esquivel‐Upshaw	1
2	Effects on Lung Tissue After Breast Cancer Radiation: Comparing Photon and Proton Therapies 2024 ·International Journal of Particle Therapy ·(unknown), Julie A. Bradley, Nancy P. Mendenhall, Raymond B. Mailhot Vega, Eric D. Brooks, Paul Okunieff, (unknown), (unknown), Karen Daily, Coy D. Heldermon, (unknown), Ji‐Hyun Lee, Steven G Swarts, Walter G. O’Dell	0
3	Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors 2024 ·Breast Cancer Research and Treatment ·Ching‐Yuan Chang, Bobby L. Jones, Juan M. Hincapie‐Castillo, Haesuk Park, Coy D. Heldermon, Vakaramoko Diaby, Debbie L. Wilson, Wei‐Hsuan Lo‐Ciganic	1
4	Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors 2024 ·British Journal of Cancer ·Ching‐Yuan Chang, Bobby L. Jones, Juan M. Hincapie‐Castillo, Haesuk Park, Coy D. Heldermon, Vakaramoko Diaby, Debbie L. Wilson, Wei‐Hsuan Lo‐Ciganic	4
5	Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector 2022 ·Human Molecular Genetics ·(unknown), (unknown), (unknown), (unknown), (unknown), Mi‐Jung Kim, Shinichi Someya, (unknown), Michael H. Gelb, (unknown), Elizabeth A. Butterworth, Darin J. Falk, (unknown), (unknown), Hamid Khaledi, (unknown), (unknown), Coy D. Heldermon	5
6	Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death 2022 ·Cancer Letters ·Mary E. Law, (unknown), (unknown), Bradley J. Davis, Renan B. Ferreira, Jin Koh, Sixue Chen, (unknown), (unknown), (unknown), Coy D. Heldermon, Peter Nørgaard, Ronald K. Castellano, Brian K. Law	15
7	LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease 2021 ·SHILAP Revista de lepidopterología ·Hoda Safari Yazd, (unknown), (unknown), (unknown), Coy D. Heldermon, Mark S. Segal, (unknown), William L. Clapp, Timothy J. Garrett	8
8	The beta-glucuronidase intracisternal A particle insertion model results in similar overall MPSVII phenotype as the single base deletion model when on the same C57BL/6J mouse background 2021 ·Molecular Genetics and Metabolism Reports ·(unknown), (unknown), Colleen G. Le Prell, Thomas J. Wronski, J. Ignacio Aguirre, (unknown), Coy D. Heldermon	0
9	Generation of Induced Pluripotent Stem Cells from a Female Patient with a Xq27.3-q28 Deletion to Establish Disease Models and Identify Therapies 2020 ·Cellular Reprogramming ·(unknown), (unknown), Katherine E. Santostefano, (unknown), (unknown), Coy D. Heldermon, Daisuke Tachibana, Masayasu Koyama, Amy Meacham, Christina A. Pacak, Naohiro Terada	4
10	Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse 2020 ·Gene Therapy ·(unknown), (unknown), (unknown), Ronald J. Mandel, Sanford L. Boye, Arun Srivastava, Coy D. Heldermon	12
11	An Erythritol-Sweetened Beverage Induces Satiety and Suppresses Ghrelin Compared to Aspartame in Healthy Non-Obese Subjects: A Pilot Study 2020 ·Cureus ·Zachary A. Sorrentino, Garrett Smith, (unknown), (unknown), John Butterfield, (unknown), Rebecca Henderson, Coy D. Heldermon, Shiva Gautam, Mark Brantly	8
12	Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway 2019 ·Cell Death Discovery ·Mengxiong Wang, Mary E. Law, Bradley J. Davis, (unknown), (unknown), Renan B. Ferreira, Chi-Wu Chiang, Olga A. Guryanova, Daniel Kopinke, Coy D. Heldermon, Ronald K. Castellano, Brian K. Law	9
13	A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells 2019 ·Biochemical Journal ·Mam Y. Mboge, Zhijuan Chen, (unknown), (unknown), Lingbao Ai, Coy D. Heldermon, Murat Bozdağ, Fabrizio Carta, Claudiu T. Supuran, Kevin D. Brown, Robert McKenna, Christopher J. Frost, Susan C. Frost	28
14	Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells 2018 ·PLoS ONE ·Zhijuan Chen, Lingbao Ai, Mam Y. Mboge, Chingkuang Tu, Robert McKenna, Kevin D. Brown, Coy D. Heldermon, Susan C. Frost	51
15	Novel agents that downregulate EGFR, HER2, and HER3 in parallel 2015 ·Oncotarget ·Renan B. Ferreira, Mary E. Law, Stephan C. Jahn, Bradley J. Davis, Coy D. Heldermon, Mary K. Reinhard, Ronald K. Castellano, Brian K. Law	24
16	High resolution functional photoacoustic tomography of breast cancer 2015 ·Medical Physics ·Xiaoqi Li, Coy D. Heldermon, Lei Yao, Lei Xi, Huabei Jiang	54
17	TRIM29 Suppresses TWIST1 and Invasive Breast Cancer Behavior 2014 ·Cancer Research ·Lingbao Ai, (unknown), Merve Alpay, Ming Tang, Carolina Pardo‐Díaz, Shigetsugu Hatakeyama, W. Stratford May, Michael P. Kladde, Coy D. Heldermon, Erin M. Siegel, Kevin D. Brown	76
18	Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice 2013 ·Gene Therapy ·Coy D. Heldermon, (unknown), (unknown), Erik D. Herzog, Jeremy R. Glissen Brown, Carole Vogler, Wei Hou, John L. Orrock, Brett E. Crawford, Mark S. Sands	31
19	Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIB 2010 ·Molecular Therapy ·Coy D. Heldermon, Kevin K. Ohlemiller, Erik D. Herzog, Carole Vogler, Elizabeth Y. Qin, David F. Wozniak, Yun Tan, John L. Orrock, Mark S. Sands	52
20	Site-directed mutation of conserved cysteine residues does not inactivate the Streptococcus pyogenes hyaluronan synthase 2001 ·Glycobiology ·Coy D. Heldermon, Valarie L. Tlapak‐Simmons, Bruce A. Baggenstoss, Paul H. Weigel	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact